All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

NICE recommends KTE-X19 for the treatment of R/R MCL

Jan 21, 2021
Share:

On January 19, 2021, the National Institute for Health and Care Excellence (NICE) for England issued guidance stating that KTE-X19 could be considered under a managed access agreement, via the Cancer Drugs Fund, for the treatment of adult patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL), who have previously received treatment with a Bruton’s tyrosine kinase inhibitor.1

KTE-X19, an autologous, anti-CD19-transduced CD3+, chimeric antigen receptor-T cell therapy, has previously been granted approval by the U.S. Food and Drug Administration (FDA) and a conditional approval by the European Medicines Agency (EMA) for the treatment of R/R MCL.

The NICE recommendation was based on results of the ongoing phase II ZUMA-2 study (NCT02601313), in a modified intent-to-treat group (n = 68). Results showed a promising overall response rate and an extension to life for patients that achieved a complete response to KTE-X19. However, at the latest data cut-off (December 2020), the median follow-up time was short, and the survival data were immature. Therefore, the NICE committee have asked for further data to be collected on progression-free survival and overall survival. A 3-year follow up is needed to provide reliable evidence of a cure.2

Currently, the National Health Service (NHS) has ten providers around the country that will be able to offer KTE-X19 as a treatment option for R/R MCL.1

  1. National Institute for Health and Care Excellence (NICE). NHS patients to benefit from first full access deal in Europe for new CAR-T therapy recommended by NICE. https://www.nice.org.uk/news/article/nhs-patients-to-benefit-from-first-full-access-deal-in-europe-for-new-car-t-therapy-recommended-by-nice. Published Jan 19, 2021. Accessed Jan 20, 2021.
  2. National Institute for Health and Care Excellence (NICE). Final appraisal document. Autologous anti-CD19-transduced CD3+ cells for treating relapsed or refractory mantle cell lymphoma. https://www.nice.org.uk/guidance/gid-ta10312/documents/final-appraisal-determination-document. Published Jan 19, 2021. Accessed Jan 20, 2021.

Share: